Skip to main content
Premium Trial:

Request an Annual Quote

Spartan Bioscience Taps Germany's Alere to Distribute CYP2C19 Testing Platform

Premium

Canadian molecular diagnostics shop Spartan Bioscience said today that it has inked an exclusive distribution agreement with Germany's Alere GmbH to distribute the Spartan RX CYP2C19 platform in Germany, Austria, and Switzerland.

This is Spartan's first distribution deal for RX CYP2C19, a PCR-based point-of-care platform that tests for the CYP2C19*2 mutation that impairs metabolization of the anti-coagulant Plavix. The distribution agreement comes on the heels of the platform receiving a CE Mark for in vitro diagnostic use (PCR Insider, 12/23/2010).

Alere GmbH, a Koln-based subsidiary of Waltham, Mass.-based Alere, will concentrate its efforts on reaching customers in surgery suites and catheterization labs at hospitals and medical centers, Spartan said.

In a statement, Dave Sieber, managing director of Alere GmbH, called the Spartan RX CYP2C19 "an excellent fit with our expertise in the cardiology market."

Spartan has also applied for regulatory approval for the RX CYP2C19 in the US and Canada, and is targeting the third quarter of this year to receive such approvals. Spartan launched the Spartan RX CYP2C19 platform in August (PCR Insider, 8/12/2010).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more